Clinical significance of preoperative serum sialic acid levels in colorectal cancer:: Utility in the detection of patients at high risk of tumor recurrence

被引:23
作者
Feijoo-Carnero, C [1 ]
Rodríguez-Berrocal, FJ [1 ]
de la Cadena, MN [1 ]
Ayude, D [1 ]
de Carlos, A [1 ]
Martínez-Zorzano, VS [1 ]
机构
[1] Univ Vigo, Dept Biochem Genet & Immunol, Vigo, Spain
关键词
colorectal cancer; sialic acid; tumor marker; disease-free survival; prognosis;
D O I
10.1177/172460080401900105
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
This study was conducted to evaluate the significance of preoperative serum sialic acid levels in the diagnosis and prognosis of colorectal cancer (CRC). Total sialic acid (TSA) was determined by the thiobarbituric acid method and normalized to total protein (TP). A postoperative follow-up of CRC patients classified as Dukes' stages A, B or C was performed and survival analysis was carried out to evaluate the impact of sialic acid levels on tumor recurrence. Our diagnostic studies indicate that TSA/TP is a better marker than either TSA or carcinoembryonic antigen (CEA), especially for the detection of CRC patients at an early stage. At a cutoff of 30.90 nmol/mg of protein, TSA/TP showed a sensitivity of 85% with a specificity of 97% to discriminate CRC patients from healthy donors. In survival analysis, both TSA and TSA/TP were found to be significant prognostic factors for tumor recurrence in CRC. Furthermore, TSA/TP could distinguish patients at high risk of recurrence within Dukes' stage B and in multivariate analysis it was identified as the best independent prognostic factor. According to our results, preoperative serum TSA/TP content could supply additional information to that provided by Dukes' stage about the prognosis of CRC patients.
引用
收藏
页码:38 / 45
页数:8
相关论文
共 32 条
[2]   Value of the serum alpha-L-fucosidase activity in the diagnosis of colorectal cancer [J].
Ayude, D ;
Fernández-Rodríguez, J ;
Rodríguez-Berrocal, FJ ;
Martínez-Zorzano, VS ;
de Carlos, A ;
Gil, E ;
de la Cadena, MP .
ONCOLOGY, 2000, 59 (04) :310-316
[3]  
BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13
[4]   Serum YKL-40 and colorectal cancer [J].
Cintin, C ;
Johansen, JS ;
Christensen, IJ ;
Price, PA ;
Sorensen, S ;
Nielsen, HJ .
BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1494-1499
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines [J].
Duffy, MJ ;
van Dalen, A ;
Haglund, C ;
Hansson, L ;
Klapdor, R ;
Lamerz, R ;
Nilsson, O ;
Sturgeon, C ;
Topolcan, O .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (06) :718-727
[7]   The classification of cancer of the rectum [J].
Dukes, CE .
JOURNAL OF PATHOLOGY AND BACTERIOLOGY, 1932, 35 (03) :323-332
[8]  
ERBIL KM, 1985, CANCER, V55, P404, DOI 10.1002/1097-0142(19850115)55:2<404::AID-CNCR2820550219>3.0.CO
[9]  
2-Q
[10]   Sialic acid levels in serum and tissue from colorectal cancer patients [J].
Feijoo, C ;
delaCadena, MP ;
RodriguezBerrocal, FJ ;
MartinezZorzano, VS .
CANCER LETTERS, 1997, 112 (02) :155-160